Environmental impact and costs of a switching program of intravenous to subcutaneous infliximab in Inflammatory Bowel Disease

• Author(s): Oliveira, R. ; Roseira, J. ; Araújo, N. ; Cavaco, C. ; André, J. ; Sousa, M. ; Sousa, H. Tavares de ; Cunha, M.
• Date: 2025
• Persistent ID: http://hdl.handle.net/10400.1/26862
• Origin: Sapientia - Universidade do Algarve
• Document Type: Conference object
• Language: English
• Contributor(s): Sapientia

Description

We aimed to compare real-life direct and indirect costs and the environmental impact of switching IBD patients from IV to SC infliximab (IFX).